Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking. METHODS: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety. RESULTS: At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium. CONCLUSIONS: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is also approved for treatment in men and women at high risk of fracture with osteoporosis associated with sustained systemic glucocorticoid therapy [91].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [91]
In the citing paper
“In support of this notion, it is reported that anabolic agent, hPTH (1-34), is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) populations for both men and women [11, 47-49].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [11]
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Self-citationIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Research works printed but not linked: 2
- Sambrook PN, 2001, Aust Fam Physician, 30, 793
- Mudano A, 2001, J Rheumatol, 28, 1298
Cited by
Items 301–400 of 910
Combination Anabolic and Antiresorptive Therapy for Osteoporosis
Cusano, N. E., & Bilezikian, J. P. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.005 · Cited by 26
Medical Treatment of Osteoporotic Vertebral Fractures
Langdahl, B. L., & Harsløf, T. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10392105 · Cited by 31
Osteoporosis premenopáusica: ¿cómo tratarla?
Martínez‐Morillo, M., Grados, D., & Holgado, S. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.05.011 · Cited by 28
Cosman, F., Oates, M. K., Betah, D., Timoshanko, J., Wang, Z., Ferrari, S., & McClung, M. R. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae116 · Cited by 32
Mechanisms Underlying Medication‐Related Osteonecrosis of the Jaw
Lee, K., Kim, K., Kim, J. Y., Kim, J., Kang, Y., Kim, Y. H., & Kim, S. (2024) · Oral Diseases · doi:10.1111/odi.15198 · Cited by 37
Current and future treatments of secondary osteoporosis
Soriano, R., Herrera, S., Nogués, X., & Díez‐Pérez, A. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.004 · Cited by 29
Osteoporosis after renal transplantation
Dounousi, E. C., Leivaditis, K., Eleftheriadis, T., & Liakopoulos, V. (2014) · International Urology and Nephrology · doi:10.1007/s11255-014-0862-3 · Cited by 25
Messina, O. D., Vidal, M., Torres, J. A. M., Vidal, L. F., Arguissain, C., Pereira, R. M. R., Clark, P., Pérez, S. C., Campusano, C., Lazaretti‐Castro, M., et al. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02261-2 · Cited by 27
Lewiecki, E. M., Czerwinski, E. J., Recknor, C. P., Strzelecka, A., Valenzuela, G., Lawrence, M., Silverman, S. L., Cardona, J., Nattrass, S., Binkley, N., et al. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4877 · Cited by 47
Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons
Clay, P. G., Voss, L. E., Williams, C., & Daume, E. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k465 · Cited by 25
Conservative Treatment for Minimally Displaced Type B Periprosthetic Femoral Fractures
Lee, Y., Kim, J.-T., Kim, K.-C., Ha, Y., & Koo, K. (2017) · The Journal of Arthroplasty · doi:10.1016/j.arth.2017.05.057 · Cited by 25
Current Status of Bone-Forming Therapies for the Management of Osteoporosis
Sølling, A. S., Harsløf, T., & Langdahl, B. L. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00675-8 · Cited by 25
Rheumatic manifestations of endocrine disease
Chakravarty, S. D., & Markenson, J. A. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835b4f3f · Cited by 25
Clinical update on teriparatide
File, E., & Deal, C. L. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0023-3 · Cited by 27
Shangguan, L., Ding, M. L., Wang, Y., Xu, H., & Liao, B. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.03.019 · Cited by 27
Shi, Y., Tang, Q., Sheng, S., Jiang, H., Jin, C., Zhou, C., Xie, C., Zheng, L., Zhang, D., Xu, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202414902 · Cited by 33
Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis
Moore, A. E. B., Blake, G. M., Taylor, K. A., Ruff, V. A., Rana, A. E., Wan, X., & Fogelman, I. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1974-y · Cited by 24
Self-citationTeriparatide increases bone mineral density in a man with osteoporosis pseudoglioma
Arantes, H. P., Barros, E. R., Kunii, I. S., Bilezikian, J. P., & Lazaretti‐Castro, M. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.530 · Cited by 24
Kimura, S., Nakagawa, T., Matsuo, Y., Ishida, Y., Okamoto, Y., & Hayashi, M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.07.015 · Cited by 24
Severe hypercalcemia due to teriparatide
Karatoprak, C., Kayataş, K., Kilicaslan, H., Yolbaş, S., Yazimci, N., Gümüskemer, T., & Demirtunç, R. (2012) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.93869 · Cited by 24
Association between osteoporosis and rheumatoid arthritis in women: a cross-sectional study
Sarkis, K. S., Salvador, M. B., Pinheiro, M. A. A., Silva, R. G., Zerbini, C. A. F., & Martini, L. A. (2009) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802009000400007 · Cited by 25
Management of glucocorticoids-induced osteoporosis: role of teriparatide
Migliaccio, S., Brama, M., & Malavolta, N. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3940 · Cited by 30
Clinical Question: What is the best approach to managing glucocorticoid-induced osteoporosis?
Compston, J. E. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.03994.x · Cited by 23
The role of teriparatide in sequential and combination therapy of osteoporosis
Meier, C., Lamy, O., Krieg, M., Mellinghoff, H.-U., Felder, M., Ferrari, S., & Rizzoli, R. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.13952 · Cited by 27
Rheumatic manifestations of endocrine diseases
Markenson, J. A. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328333dd38 · Cited by 23
Ren, H. J., Shen, G., Tang, J., Qiu, T., Zhang, Z., Zhao, W., Yu, X., Huang, J., Liang, D., Yao, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10614-5 · Cited by 24
When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis
Hayes, K. N., Baschant, U., Hauser, B., Burden, A. M., & Winter, E. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.782118 · Cited by 31
Oleanolic acid ameliorates high glucose-induced endothelial dysfunction via PPARδ activation
Zhang, Z., Jiang, M., Xie, X., Yang, H., Wang, X., Xiao, L., & Wang, N. (2017) · Scientific Reports · doi:10.1038/srep40237 · Cited by 24
Glucocorticoid- and Transplantation-Induced Osteoporosis
Zavatta, G., & Clarke, B. L. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.002 · Cited by 23
Compston, J. E. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad029 · Cited by 29
Guías 2012 para el diagnóstico, la prevención y el tratamiento de la osteoporosis
Schurman, L., Bagur, A., Claus-Hermberg, H., Messina, O. D., Negri, A. L., Sánchez, A., González, C. D., Diehl, M., Rey, P., Gamba, J., et al. (2013) · Actualizaciones en osteología · Cited by 31
Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis
Rizzoli, R. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09352920 · Cited by 22
Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options
Payer, J., Brázdilová, K., & Jackuliak, P. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s7197 · Cited by 23
Lewiecki, E. M., Miller, P. D., Harris, S. T., Bauer, D. C., Davison, K. S., Dian, L., Hanley, D. A., McClung, M. R., Yuen, C. K., & Kendler, D. L. (2013) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.09.018 · Cited by 26
Tsujimoto, M., Uenaka, K., Iwata, A., Higashiuchi, Y., & Sowa, H. (2011) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-011-0314-4 · Cited by 22
Lu, M., & Zhao, X. (2018) · Molecules · doi:10.3390/molecules23061287 · Cited by 23
Lavaill, M., Trichilo, S., Scheiner, S., Forwood, M. R., Cooper, D. M. L., & Pivonka, P. (2020) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-020-01307-6 · Cited by 22
Glucocorticoid-Induced Osteoporosis ? A Disorder of Mesenchymal Stromal Cells?
Hardy, R., & Cooper, M. S. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00024 · Cited by 23
Glucocorticoid-Induced Osteoporosis: Management Update
Adler, R. A. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0003-6 · Cited by 21
Asia-Pacific consensus on long-term and sequential therapy for osteoporosis
Tai, T., Chen, H., Shih, C., Huang, C., McCloskey, E. V., Lee, J. K., Yeap, S. S., Cheung, C., Charatcharoenwitthaya, N., Jaisamrarn, U., et al. (2024) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2024.02.001 · Cited by 27
Self-citationTabatabai, L. S., Cosman, F., Curtis, J. R., DeSapri, K. T., LaBaume, C. T., Reginster, J., Rizzoli, R., Cortet, B., Wang, Y., Chiodo, J., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.10.017 · Cited by 27
Fujita, S.-I., Okamoto, Y., Shibata, K., Morita, H., Ito, T., Sohmiya, K., Hoshiga, M., & Ishizaka, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082735 · Cited by 22
Glucocorticoid-induced osteoporosis: hope on the HORIZON
Gennari, L., & Bilezikian, J. P. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60704-2 · Cited by 21
Selective glucocorticoid receptor agonists: Glucocorticoid therapy with no regrets?
Cooper, M. S., Zhou, H., & Seibel, M. J. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1753 · Cited by 21
Atypical diaphyseal femoral fractures—new aspects
Feldman, F. (2011) · Skeletal Radiology · doi:10.1007/s00256-011-1130-6 · Cited by 24
Cysteine Cathepsins: Markers and Therapy Targets in Lung Disorders
Kasabova, M., Saidi, A., Naudin, C., Sage, J., Lecaille, F., & Lalmanach, G. (2011) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-011-9094-6 · Cited by 29
Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
Park, S. Y., Gong, H. S., Kim, K. M., Kim, D., Kim, H. Y., Jeon, C. H., Ju, J. H., Lee, S., Park, D. A., Sung, Y., et al. (2018) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2018.25.4.263 · Cited by 21
Nasomyont, N., Keefe, C., Tian, C., Hornung, L. N., Khoury, J. C., Tilden, J. C., Hochwalt, P., Jackson, E., Rybalsky, I., Wong, B. L. Y., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05549-z · Cited by 21
Liu, Z., Zhang, M., Shen, Z., Ke, J., Zhang, D., & Yin, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243851 · Cited by 24
Anabolic treatments for osteoporosis in postmenopausal women
Hassan, N., Gregson, C. L., & Tobias, J. H. (2021) · Faculty Reviews · doi:10.12703/r/10-44 · Cited by 23
Kuriwaka-Kido, R., Kido, S., Miyatani, Y., Ito, Y., Kondo, T., Omatsu, T., Dong, B., Endo, I., Miyamoto, K., & Matsumoto, T. (2013) · Endocrinology · doi:10.1210/en.2013-1915 · Cited by 21
Glucocorticoids in bone and joint disease: the good, the bad and the uncertain
Cooper, M. S. (2012) · Clinical Medicine · doi:10.7861/clinmedicine.12-3-261 · Cited by 22
Short Anabolic Peptides for Bone Growth
Amso, Z., Cornish, J., & Brimble, M. A. (2016) · Medicinal Research Reviews · doi:10.1002/med.21388 · Cited by 21
Briot, K. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.04.016 · Cited by 24
PTHG2 Reduces Bone Loss in Ovariectomized Mice by Directing Bone Marrow Mesenchymal Stem Cell Fate
Chen, J., Zhang, H., Wu, X., Wang, F., Wang, Y., Gao, Q., Liu, H., Hu, Y., Su, J., & Jing, Y. (2021) · Stem Cells International · doi:10.1155/2021/8546739 · Cited by 22
Medical treatment of severe osteoporosis including new concept of advanced severe osteoporosis
Choi, H. S., Park, S. Y., Kim, Y. M., Kim, S. H., Kim, K. M., & Chung, Y. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.02.003 · Cited by 20
Lorenzo, J. A., CANALIS, E. M., & Raisz, L. G. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00029-8 · Cited by 23
Romosozumab, clinical trials, and real-world care of patients with osteoporosis
Lewiecki, E. M. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.196 · Cited by 18
Ahlström, M., Pekkinen, M., & Lamberg-Allardt, C. J. E. (2008) · Steroids · doi:10.1016/j.steroids.2008.12.002 · Cited by 22
Combination antiresorptive and osteoanabolic therapy for osteoporosis: We are not there yet
Cusano, N. E., & Bilezikian, J. P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.599837 · Cited by 21
Zdrojowy-Wełna, A., Stachowska, B., & Bolanowski, M. (2024) · Pituitary · doi:10.1007/s11102-024-01427-7 · Cited by 24
A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Dedov, I. I., Drapkina, O. M., Fadeev, V. V., Golounina, O. O., Lesnyak, O. M., Mamedova, E., Mel'nichenko, G. A., Petraikin, A. V., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-022-06667-6 · Cited by 24
Perioperative Treatment of Patients with Rheumatoid Arthritis
Saleh, K. J., Kurdi, A. J., El‐Othmani, M. M., Voss, B. A., Tzeng, T. H., Saleh, J., Lane, J. M., & Mihalko, W. M. (2015) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-15-00014 · Cited by 18
Glucocorticoid Attenuates the Anabolic Effects of Parathyroid Hormone on Fracture Repair
Doyon, A. R., Ferries, I. K., & Li, J. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9370-3 · Cited by 21
Brent, M. B., Thomsen, J. S., & Brüel, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-91729-8 · Cited by 19
Prevention of glucocorticoid-induced osteoporosis
van Brussel, M., Bultink, I. E. M., & Lems, W. F. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902868225 · Cited by 20
II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopáusica
Orjuela, A. M., Rosero, O., Rueda-Plata, P. N., Escobar, F. S., Chalem, M., Reyes, M., Román-Gonzaléz, A., Lozano, A. T., Talero, A. P., Beltz, C. R., et al. (2018) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2018.02.006 · Cited by 49
Sethi, B. K., Chadha, M. D., Modi, K. D., KUMAR, K. M. P., Mehrotra, R., & Sriram, U. (2008) · PubMed · Cited by 21
Kenanidis, E. I., Potoupnis, M. E., Kakoulidis, P., Leonidou, A. O., Sakellariou, G. T., Sayegh, F. E., & Tsiridis, E. E. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1040387 · Cited by 21
Glucocorticoid-induced osteoporosis: 2013 update
Mazzantini, M., & Munno, O. D. (2014) · Reumatismo · doi:10.4081/reumatismo.2014.787 · Cited by 22
Osteoanabolic therapy for osteoporosis in women
McClung, M. R., & Clark, A. (2021) · Climacteric · doi:10.1080/13697137.2021.1953463 · Cited by 20
Herath, M., Langdahl, B. L., Ebeling, P. R., & Milat, F. (2021) · Clinical Endocrinology · doi:10.1111/cen.14637 · Cited by 21
The role of osteoanabolic agents in the management of patients with osteoporosis
McClung, M. R., Rothman, M. S., Lewiecki, E. M., Hanley, D. A., Harris, S. T., Miller, P. D., & Kendler, D. L. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2069582 · Cited by 20
Position Statement: Vitamin D Intake to Prevent Osteoporosis and Fracture in Adults
Han, A., Park, Y., Lee, Y., Park, S. Y., & Park, C. Y. (2022) · Journal of Bone Metabolism · doi:10.11005/jbm.2022.29.4.205 · Cited by 22
Tripto‐Shkolnik, L., Szalat, A., Tsvetov, G., Rouach, V., Sternberg, C., Hoppe, A., Burshtein, G., Galitzer, H., Toledano, M., Harari, G., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae057 · Cited by 20
A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman
Han, J. Y., Lee, J., Kim, G. E., Yeo, J. Y., Kim, S. H., Nam, M., Kim, Y., & Hong, S. (2012) · Journal of Bone Metabolism · doi:10.11005/jbm.2012.19.2.153 · Cited by 19
Clinical Use of Bone Turnover Markers to Monitor Pharmacologic Fracture Prevention Therapy
Schousboe, J. T., & Bauer, D. C. (2012) · Current Osteoporosis Reports · doi:10.1007/s11914-011-0091-y · Cited by 19
Aloumanis, K., Karras, D., Drossinos, V., Korelis, E., & Polydorakis, A. (2011) · Journal of Osteoporosis · doi:10.4061/2011/510398 · Cited by 18
Strategy and Tactics for Designing Analogs: Biochemical Characterization of the Large Molecules
Ahn, J., Kassees, K., Lee, T.-K., Manandhar, B., & Yousif, A. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12413-8 · Cited by 24
Management of glucocorticoid-related osteoporotic vertebral fracture
Wong, S. P. Y., & Mok, C. C. (2020) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2020.02.002 · Cited by 19
Losada, B. R., Zanchetta, J., Zerbini, C. A. F., Molina, J. F., la Peña, P. D., Liu, C. C., Smith, R. B., Nino, A., Krohn, K., & Warner, M. R. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.10.002 · Cited by 20
Lower Spine Volumetric Bone Density in Patients With a History of Epidural Steroid Injections
Liu, Y., Carrino, J. A., Dash, A. S., Chukir, T., Do, H. T., Bockman, R. S., Hughes, A. P., Press, J. M., & Stein, E. M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00558 · Cited by 18
The conundrum of glucocorticoid-induced osteoporosis
Teitelbaum, S. L. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.89 · Cited by 19
Advances in Parathyroid Hormone-based medicines
Bonnet, A., Aboishava, L. A., & Mannstadt, M. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf118 · Cited by 19
Dong, L., Jiang, L., Xu, Z., & Zhang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1336075 · Cited by 18
Yu, D., Kim, S., & Jeon, I. (2020) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2020.0110 · Cited by 17
Management of difficult osteoporosis
Russell, L. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.04.002 · Cited by 20
Management of osteoporosis in the aging male: Focus on zoledronic acid
Piper, P. K., & Gruntmanis, U. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4295 · Cited by 18
The Anabolic Response to Parathyroid Hormone Is Augmented in Rac2 Knockout Mice
Kawano, T., Troiano, N. W., Adams, D. J., Wu, J. J., Sun, B., & Insogna, K. L. (2008) · Endocrinology · doi:10.1210/en.2008-0034 · Cited by 19
Clinical Update on Nursing Home Medicine: 2008
Messinger‐Rapport, B. J., Thomas, D. R., Gammack, J. K., & Morley, J. E. (2008) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2008.07.006 · Cited by 17
Harlow, L., Sahbani, K., Nyman, J. S., Cardozo, C. P., Bauman, W. A., & Tawfeek, H. A. W. (2017) · Physiological Reports · doi:10.14814/phy2.13446 · Cited by 20
Operationalizing Treat-to-Target for Osteoporosis
Lewiecki, E. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.970 · Cited by 17
Dong, B., Zhou, Y., Wang, J., Li, C., Fu, Z., Huang, Y., Wang, Y., & Xu, L. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2015-1747 · Cited by 18
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
Anastasilakis, A. D., Yavropoulou, M. P., Palermo, A., Makras, P., Paccou, J., Tabacco, G., Naciu, A. M., & Tsourdi, E. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae076 · Cited by 17
Bisphosphonates and glucocorticoid-induced osteoporosis: Efficacy and tolerability
Lespessailles, É. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.08.005 · Cited by 17
Update on osteoporosis from the 2014 Santa Fe Bone symposium
Lewiecki, E. M., Bilezikian, J. P., Binkley, N., Hans, D. B., Krueger, D. C., Miller, P. D., Oates, M. K., & Shane, E. J. (2015) · Endocrine Research · doi:10.3109/07435800.2015.1005746 · Cited by 16
Self-citationMetcalf, L. M., Aspray, T., & McCloskey, E. V. (2017) · Bone · doi:10.1016/j.bone.2017.03.007 · Cited by 17
Lespessailles, É., & Chapurlat, R. D. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05568-w · Cited by 19
Summary of the draft federal clinical guidelines for osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Grebennikova, T. A., Kanis, J. А., Pigarova, E. A., Rodionova, S. S., Toroptsova, N. V., Nikitinskaya, O. A., Skripnikova, I. A., Drapkina, O. M., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12710 · Cited by 20
Sugie-Oya, A., Takakura, A., Takao-Kawabata, R., Sano, H., Shimazu, Y., Isogai, Y., Yamaguchi, A., & Ishizuya, T. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0670-6 · Cited by 19
Metadata
- Authors
- Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R.
- Affiliations
- University of Alabama at Birmingham (US)
- Columbia University (US)
- KU Leuven (BE)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2028-2039
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2042007405
- Cited by
- 914
- References
- 40
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 36 · 2023: 32 · 2022: 45 · 2021: 56 · 2020: 43 · 2019: 38 · 2018: 53 · 2017: 35 · 2016: 33 · 2015: 51 · 2014: 49 · 2013: 59 · 2012: 61
- FWCI
- 63.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- teriparatide, alendronate, glucocorticoid-induced osteoporosis, bisphosphonates, bone mineral density, vertebral fractures, non-vertebral fractures, fracture risk, serum calcium, bone turnover markers, anabolic therapy
- MeSH terms
- Aged, Aged, 80 and over, Calcium, Double-Blind Method, Female, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Risk, Biomarkers, Bone Density, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.